A multicentre study of thromboprophylaxis in pregnancy by Crowley, Maeve P. et al.
UCC Library and UCC researchers have made this item openly available.
Please let us know how this has helped you. Thanks!
Title A multicentre study of thromboprophylaxis in pregnancy
Author(s) Crowley, Maeve P.; Noone, C.; Higgins, John R.; O'Shea, S.
Publication date 2017-05
Original citation Crowley, M. P., Noone, C., Higgins, J. R. and O'Shea, S. (2017) 'A
multicentre study of thromboprophylaxis in pregnancy', Irish Medical
Journal, 110(5), 567 (9pp).  doi:10147/621373
Type of publication Article (peer-reviewed)
Link to publisher's
version
http://dx.doi.org/10147/621373
Access to the full text of the published version may require a
subscription.
Rights © 2017, Irish Medical Journal. All rights reserved.
Item downloaded
from
http://hdl.handle.net/10468/5891
Downloaded on 2019-12-02T14:30:14Z
A multicentre study of thromboprophylaxis in pregnancy. – Irish Medical Journal
file:///nas.ucc.ie/Groups/Cora/Scopus/Accepted Versions/A multicentre study of thromboprophylaxis in pregnancy. – Irish Medical Journal.html[27/04/2018 10:08:28]
A Multicentre Study of Thromboprophylaxis in
Pregnancy.
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Westminster 
Abstract
Venous thromboembolism (VTE) is a leading cause of maternal mortality. The risk increases with
increasing maternal age, mode of delivery and medical co-morbidities. Thromboprophylaxis with
low molecular weight heparin (LMWH) has been shown to be both safe and efficacious. The aim of
this study was to prospectively investigate the incidence of maternal risk factors in pregnant
women admitted to hospital, to calculate their VTE risk status and to investigate if they were
receiving appropriate thromboprophylaxis. All patients admitted to the participating hospitals on
the day of investigation were assessed for risk of VTE on the basis of hospital chart review. Five
Hundred and forty women were recruited from 16 hospitals. Almost 32% (31.7%) were receiving
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thromboprophylaxis with LMWH. Just under 80% of patients were on the correct
thromboprophylaxis strategy as defined by the RCOG guideline but 49% were under-dosed. The
odds of receiving appropriate thromboprophylaxis were significantly increased if the woman was
>35 years 0or with parity>3.
Introduction
Venous thromboembolism (VTE) remains a major cause of maternal morbidity and mortality complicating one in a
thousand pregnancies. In Ireland, VTE is the leading cause of direct maternal deaths. Recent evidence suggests that
the introduction of widespread thromboprophylaxis may have led to a decrease in deaths from VTE. The likelihood
of VTE in pregnancy is higher when additional risk factors such as a history of VTE, obesity, increased maternal age
and smoking are present. The incidence of these co-morbid conditions is increasing. The potential for a
multiplicative effect on overall VTE risk has been shown to be an important factor to consider when risk-stratifying
pregnant women. Most risk factors appear to have a greater effect on the incidence of VTE in the postpartum period
rather than in the antepartum period. Low molecular weight heparin (LMWH) has been shown to be safe and
efficacious in pregnancy. When compared with unfractionated heparin, it has been shown to be associated with a
lower risk of osteoporosis and heparin induced thrombocytopenia. It is recommended that a VTE risk assessment is
carried out on all pregnant women and thromboprophylaxis is recommended for high risk women. However, despite
thromboprophylaxis guidelines, implementation is often variable. The aim of this study was to prospectively
investigate the incidence of maternal risk factors in women admitted to maternity hospitals in Ireland, to calculate
their VTE risk status and to investigate if they were appropriately receiving thromboprophylaxis.
Methods
All maternity units in the Republic of Ireland were eligible for inclusion.  All 20 maternity units were contacted and
16 agreed to participate in the study.  Ethical approval was obtained from participating institutions. Any inpatient
wards with obstetric patients were included. Labour wards, outpatient clinics, theatres, radiology, and emergency
rooms were excluded. Data were collected from a review of hospital charts on standard case report forms by two of
the authors (physicians). Each hospital was assessed on one pre-specified day to allow complete and systemic
processing of patient data. For inclusion, each patient had to be an inpatient in an eligible ward on the day it was
surveyed and be pregnant or have delivered during the current admission. Data abstraction from all eligible charts
was completed in selected wards at each hospital on the day of hospital visitation and included patient
demographics, admission diagnosis, details of pregnancy, risk factors associated with VTE (as defined in the RCOG
Green Top  guideline No. 37a ) background medical issues, delivery details (if post-natal) and details of12
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thromboprophylaxis. The study period was September 2011 to November 2012. Patients were excluded from the
study if their charts were unavailable for review. Enrolled patients were assessed for risk of VTE and need for
thromboprophylaxis in accordance with the RCOG guideline. When assessing whether prophylaxis was compliant
with the guideline, both the type and dose of thromboprophylaxis was considered. Duration of dose was recorded if
recorded in the medical chart.
Quantitative data was described using mean and standard deviation (SD) if normally distributed and median and
interquartile range (IQR) if non-normally distributed. Categorical data was summerised into number (N) and
percentage (%). Comparison between groups was performed using Fisher’s exact test for categorical variables. The
likelihood of receiving appropriate thromboprophylaxis was calculated by multivariate binary logistic regression
analyses. Likelihoods were expressed as odds ratios (ORs).  Analysis were performed using Predictive Analytical
Software (PASW) Statistics, Version 18.0 using a two-sided type 1 error rate of 0.05.    
Results
Baseline characteristics
Five hundred and forty women were recruited from 16 hospitals. The mean age at booking was 31(5.7) years (Table
1). One hundred and twenty-four women (23%) were aged over thirty-five at booking. Both antenatal and postnatal
women were included; 31.1%(168) of participants were antenatal. The median gestation of antenatal women was 35
(30-38) weeks  Eighty-six percent (465) of women had booking weights documented. The mean (SD) booking-
weight was 71.5 (14.5) kg. Seventy-eight percent (420) of women had a booking Body Mass Index (BMI) calculated
(or a height and weight documented so that a BMI could be calculated). The mean booking BMI was 26.2 (4.9)
kg/m . While 88 (16.3%) women were considered to be obese at booking, it’s important to note that 23 (4.3%) had a
BMI>35kg/m  and 6 (1.1%) had a BMI>40kg/m . The median parity was 1 with 21.7% of woman having a parity of
3 or more. Four (0.7%) women had a personal history of VTE and 17 (3.1%) had a family history of VTE. Only 7
women had undergone thrombophillia testing; two were heterozgous for the Factor V Leiden mutation and one had
antithrombin deficiency. Thirty percent (162) had an underlying medical condition that was unrelated to the
pregnancy. A wide variety of conditions were noted. Asthma was the most commonly documented, affecting 5.7%
(31); endocrine disorders were the next most common with 3.9% (21) having hypothyroidism, 2% (11) having
hyperthyroidism and 3.5% (19) having impaired glucose tolerance or diabetes mellitus. Two women had a history of
cancer (breast), three had a history of intravenous drug abuse and one had nephrotic syndrome. Eleven women had
varicose veins. Almost one in five women were actively smoking at some stage during the pregnancy. Nineteen of
the pregnancies (3.5%) were multiple (all twin) and eleven (2%) were the result of assisted reproductive therapies.
No woman had undertaken long-haul travel during her pregnancy. 
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Pregnancy morbidity   
Twenty-eight women (5.2%) had experienced hyperemesis gravidarum and six (1.6%) experienced systemic
infection necessitating admission during their pregnancy. Twenty-two (5.9%) had pre-eclampsia/suspected pre-
eclampsia. Four women were dehydrated and ten were immobile during their pregnancy.
Delivery
Thirty-three (8.9%) women had prolonged labours and fourteen (3.8%) required midcavity instrumentation.
Caesarean sections accounted for 45.7% of deliveries. Twelve (3.2%) women had documented excessive blood loss.
Thromboprophylaxis
One hundred and seventy-one women (31.7%) were recieving thrombopropylaxis (Figure 1) with LMWH
(tinzaparin 92.4%; enoxaparin 7.6%). Most of the thromboprophylaxis was in the postnatal setting: 8.3% of
antenatal women; 42.2% of postnatal women. Most (62.6%) of the women on thromboprophylaxis did not have a
plan documented in their chart regarding indication or duration of thromboprophylaxis. Of those that did, 44 were
having it for one week postpartum, 1 was having it for six weeks postpartum, 5 were having it both antenatally and
for six weeks postpartum and 5 were having it while admitted. Of women recieving enoxaparin, 25% recieved 20mg
daily and 75% recieved 40mg daily. Of those recieving tinzaparin, 42.6% recieved 3,500 units daily and 57.3%
recieved 4,500 units.  Four women received therapeutic tinzaparin and three received weight-adjusted prophylactic
doses. Of those women with weights documented, 49% were under-dosed, based on their booking weight
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Risk assessments
The investigators carried out a VTE risk assessment (according RCOG guidelines) on all women, based  on
documented risk factors (Figure 2). In the antenatal group, women were considered to be high risk if they had either
a history of a single previous VTE associated with a thrombophilia/a family history of VTE/unprovoked
VTE/oestrogen related VTE or had a history of recurrent VTE (>1). It is advised that these women should be on
antenatal thromboprophylaxis. Five(3%) women were considered high risk. Women were considered intermediate
risk if they had a previous VTE that did not meet high risk criteria, known thrombophillia and no history of VTE, a
medical co-morbitiy as outlined in the guideline, a surgical procedure or two or more risk factors as outlined in the
guideline (all were inpatients). Antenatal thromboprophylaxis should be considered in these women. Eighty-six
(51.2%) women were considered intermediate risk. Women were considered low risk if they did not meet the criteria
for high or intermediate risks. Mobilisation and avoidance of dehydration is recommended in this group. Seventy-
seven (45.8%) women were considered low risk. 
In the postnatal group, women were considered high risk if they had ever had a VTE or had an indication for
antenatal thromboprophylaxis.  It is advised that they recieve at least 6 weeks of postnatal thromboprophylaxis. Two
(0.5%) women  were considered high risk. Women were considered intermediate risk if they had a caesarean section
in labour, they had an asymptomatic thrombophilia, BMI>40kg/m , their hospital admission was prolonged, they
had a medical co-morbidity as defined in the guideline or had two or more risk factors as defined by the guideline. It
was advised that these women recieve at least 7 days thromboprophylaxis and that extended thromboprophylaxis
should be considered  for women with  3 or more risk factors. One hundred and ninety-three women (51.9%) were
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considered intermediate risk. Women were considered low risk if they didn’t meet criteria for other risk groups.
Again, mobilisation and avoidance of dehydration was recommended for these women. One hundred and seventy-
seven women (47.6%) were considered low risk. Overall, 48 (18.9%) low risk women were on thromboprophylaxis,
121 (43.4%) intermediate risk women were on thromboprophylaxis and 2 (28.6%) high risk women were on
thromboprophylaxis.
Different types of maternity units were involved in this study including large obstetric units with formal obstetric
haematology services, stand alone maternity hospitals and smaller obstetric units attached to general hospitals.
When centres with formal obstetrichaematology services were compared to other units, it was found that they were
similar in terms of patient risk profiles (p=0.164) and in terms of thromboprophylaxis use (p=0.248). Overall, 73.9%
of patients were on the correct thromboprophylaxis strategy as defined by the RCOG guideline.  The odds of
receiving appropriate thromboprophylaxis were significantly increased if the woman was aged 35 or over (OR
2.311; 95%CI 1.415-3.775;p=0.001) or if parity was greater than 3 (OR1.775; 95%CI1.078-2.923;p=0.024) but not
if BMI >30 (p=0.827) orpatients had a history of VTE (p=0.999).
Discussion
Twenty-six percent of patients in this study were not on an appropriate thromboprophylactic regimen, according to
RCOG guidelines. This included 5 antenatal women who were considered high risk and 80 postnatal women who
were considered intermediate risk but were not on pharmacological  thromboprophylaxis. Of those women that
received thromboprophylaxis, almost two-thirds had no documented thromboprophylaxis plan in their notes.
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Obstetric units are busy with a high turnover of pregnant women so if thromboprophylaxis is commenced, a plan
regarding drug, dose and duration should be documented to ensure that women recieve optimal care. Almost half the
women who recieved thromboprophylaxis were on too low a dose. A wide variety of obstetric units were looked at
in this study (range of inpatients per unit: 11-105) which reflects current obstetric practice in Ireland. The mean age
at booking was 31 with almost a quarter of women aged over 35. Women aged over 35 are at an increased risk of
pregnancy related morbidity . It is a concerning trend that they are forming a large proportion of obstetric
cohorts given their high-risk nature. The mean BMI was 26.2kg/m  with 55% of patients being overweight or obese
at booking. Worryingly, 22% of patients did not have a BMI (or height and weight) documented at booking.
Increased BMI is associated with pregnancy and neonatal morbidity . It should be identified as an issue as early as
possible so that remedial action can be instigated. In the context of this study, as BMI forms part of both the
antenatal and postnatal risk assessment, patients may have been considered low risk when in fact they were
intermediate risk and may explain why some low risk patients received thromboprophylaxis.
Few patients had a personal or family history of VTE. Almost one third had an underlying medical condition which
could impact the pregnancy. Almost one in five women were actively smoking at some stage during the pregnancy.
This is despite the fact that it has long been recognised as being harmful in pregnancy . Moreover, there have been
several campaigns, both local and national, highlighting the dangers of smoking in pregnancy and resources
dedicated to smoking cessation . Since this study, a clinical practice guideline for venous thromboprophylaxis in
pregnancy  has been published by the Institute of Obstetricians and Gynaecologists, Royal College of Physicians of
Ireland and the Irish Haematology Society in 2013. It is hoped that this will lead to a simplified risk assessment of
pregnant women and improve appropriate use of thromboprophylaxis.  Following implementation of this guideline,
we plan to repeat this study.
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